Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

Stock Information for Helius Medical Technologies Inc. Class A common shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Helius Medical Technologies Inc. Class A common shares

Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements
Helius Medical Technologies Announces Reverse Stock Split
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.